Cooper CL - Search Results

1

Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.

Cooper CL, van Heeswijk RP. Cooper CL, et al. HIV Med. 2007 Jan;8(1):1-7. doi: 10.1111/j.1468-1293.2007.00426.x. HIV Med. 2007. PMID: 17305925 Free article. Review.

2

A review of low-dose ritonavir in protease inhibitor combination therapy.

Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. Cooper CL, et al. Clin Infect Dis. 2003 Jun 15;36(12):1585-92. doi: 10.1086/375233. Epub 2003 Jun 5. Clin Infect Dis. 2003. PMID: 12802760 Review.

3

Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients.

Al-Mohri H, Cooper C, Murphy T, Klein MB. Al-Mohri H, et al. HIV Med. 2005 Nov;6(6):375-8. doi: 10.1111/j.1468-1293.2005.00330.x. HIV Med. 2005. PMID: 16268817 Free article.

4

Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection.

Cooper CL, Breau C, Laroche A, Lee C, Garber G. Cooper CL, et al. HIV Med. 2006 Jan;7(1):32-7. doi: 10.1111/j.1468-1293.2005.00340.x. HIV Med. 2006. PMID: 16313290 Free article.

5

Evaluation of nevirapine-switch strategies for HIV treatment.

Cooper CL. Cooper CL. HIV Med. 2006 Nov;7(8):537-43. doi: 10.1111/j.1468-1293.2006.00418.x. HIV Med. 2006. PMID: 17105513 Free article. Review.

6

Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis.

Anema A, Mills E, Montaner J, Brownstein JS, Cooper C. Anema A, et al. HIV Med. 2008 Jan;9(1):57-61. doi: 10.1111/j.1468-1293.2008.00515.x. HIV Med. 2008. PMID: 18199173 Free article. Review.

7

Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death: a meta-regression analysis.

Mills EJ, Kelly S, Bradley M, Mollon P, Cooper C, Nachega J. Mills EJ, et al. HIV Med. 2008 Nov;9(10):849-57. doi: 10.1111/j.1468-1293.2008.00643.x. Epub 2008 Sep 12. HIV Med. 2008. PMID: 18795965 Free article. Review.

8

Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.

Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, Loutfy MR, Raboud J, Rachlis A, Ding E, Lima VD, Montaner JS, Rourke SB, Smieja M, Tsoukas C, Hogg RS; CANOC Collaboration. Cescon AM, et al. HIV Med. 2011 Jul;12(6):352-60. doi: 10.1111/j.1468-1293.2010.00890.x. Epub 2010 Nov 8. HIV Med. 2011. PMID: 21059167 Free article.

9

Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy.

Raboud J, Blitz S, Walmsley S, Thompson C, Rourke SB, Loutfy MR; Ontario HIV Treatment Network Cohort Study Team. Raboud J, et al. HIV Clin Trials. 2010 Nov-Dec;11(6):340-50. doi: 10.1310/hct1106-340. HIV Clin Trials. 2010. PMID: 21239362

10

HIV/hepatitis C virus and HIV/hepatitis B virus coinfections protect against antiretroviral-related hyperlipidaemia.

Diong C, Raboud J, Li M, Cooper C; Ontario HIV Treatment Network Cohort Study Team. Diong C, et al. HIV Med. 2011 Aug;12(7):403-11. doi: 10.1111/j.1468-1293.2010.00897.x. Epub 2011 Jan 18. HIV Med. 2011. PMID: 21244600 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

446 results

Search Page

Filters